RET Cancer Research Takes Center Stage at ASCO, May 2026
The 2026 ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago, will feature…
Irene Guijarro MunozMay 15, 2026
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026
Join the special edition of Together Separately, presented by LCRF and the Susan Wojcicki Foundation…
Irene Guijarro MunozApril 30, 2026
BioNTech’s BNT116 mRNA cancer vaccine trial currently open at MD Anderson and Johns Hopkins
Exciting news for the RET community! BioNTech’s BNT116 mRNA cancer vaccine trial now enables combination…
Irene Guijarro MunozApril 27, 2026
Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results
The findings confirm what many in the RET+ community have been hoping to see: durable…
Irene Guijarro MunozApril 24, 2026
New Global Findings from the RETgistry: Advancing Care for RET-Altered Cancers
The RETgistry study looked at tumor samples from biopsies of RET patients whose cancers stopped…
Irene Guijarro MunozApril 7, 2026
The Future of RET Therapy for NSCLC (2026 TTLC Meeting)
The IASLC 2026 Targeted Therapies of Lung Cancer (TTLC) Meeting was held on February 18th. The meeting…
Irene Guijarro MunozMarch 26, 2026
Q&A from the 2025 RET Lung Cancer Annual Webinar
Expert answers to your most pressing questions about RET-positive cancer from our scientists and pharmaceutical…
Irene Guijarro MunozMarch 24, 2026
2025 RET Cancer Research Update
Your investment in The Happy Lungs Project has resulted in very exciting RET lung cancer…
Irene Guijarro MunozDecember 19, 2025
The Role of Biomarker Testing in Early-Stage NSCLC: Why It’s Not Just for Advanced Disease
Advances in biomarker science are reshaping how patients are diagnosed with and manage early-stage lung…
Irene Guijarro MunozDecember 15, 2025
2025 RET Webinar: Meet Our Speakers
The 2025 RET Research Update is just around the corner, and we are excited to…
Irene Guijarro MunozOctober 27, 2025
